20 results about "Formononetin" patented technology

The invention relates to a traditional Chinese medicine composition which comprises more than 1.09 permillage of ephedrine hydrochloride, more than 0.86 permillage of pseudoephedrine hydrochloride, more than 0.17 permillage of peiminine, more than 0.03 permillage of peimine, more than 0.17 permillage of chrysin-7-O-glucuronide, more than 0.002 permillage of glycyrrhetinic acid, more than 11.87 permillage of amygdalin and more than 0.01 permillage of neotuberostemonine. The oral liquid is prepared from more than 2.16 per mill of glycyrrhizic acid, more than 1.97 per mill of oroxylin A, more than 1.97 per mill of oroxylin B, more than 1.23 per mill of liquiritin, more than 0.59 per mill of apiose liquiritin, more than 0.55 per mill of baicalin, more than 0.23 per mill of chlorogenic acid, more than 0.18 per mill of praeruptorin A, more than 0.15 per mill of wild melanosin, more than 0.14 per mill of methyephedrine hydrochloride, more than 0.13 per mill of isoliquiritin, more than 0.13 per mill of neochlorogenic acid and more than 0.13 per mill of cryptochlorogenic acid. The composition is prepared from more than 0.10% of peimine, more than 0.08% of baicalein, more than 0.05% of praeruptorin B, more than 0.04% of praeruptorin C, more than 0.011% of xanthoxylin and more than 0.0006% of formononetin.

The present application relates to the chemical medicine field, specifically, it relates to a kind of anti-tumor calophyllol derivative, preparation method and application, the calophyllol derivative has good inhibitory effect on thioredoxin reductase activity, and it is found that the molecule inhibits the activity of thioredoxin reductase by inhibiting the selenium cysteine of thioredoxin reductase carbon end, and then kills tumor cell, and then obtain the anti-tumor candidate drug with higher activity and better pharmacokinetic characteristics.

A small molecule composition, comprising licochalcone A, licochalcone C, licochalcone D, licochalcone E, echinatin, isoliquiritigenin, formononetin, liquiritigenin, licoflavone C, glabrol, licoisoflavone A and licoisoflavone B, and the use thereof in preparing anticancer or antitumor drugs, anti-ferroptosis drugs, or drugs for sensitization of anticancer or antitumor drugs. The small molecule composition can also be used in combination with other antitumor drugs.

The invention discloses a formononetin derivative containing piperidine-4-carbohydrazide as well as a preparation method and application of the formononetin derivative, and belongs to the technical field of pesticide synthesis. According to the invention, a piperidine-4-carbohydrazide group with excellent activity is introduced into the structure of formononetin, a series of formononetin derivatives of piperidine-4-carbohydrazide are synthesized, and the activity of the synthesized formononetin derivatives containing piperidine-4-carbohydrazide in inhibiting plant pathogens is tested. It is found that the formononetin derivative of piperidine-4-carbohydrazide synthesized by the invention can effectively inhibit plant pathogenic fungi, especially rhizoctonia solani.

The invention provides application of a group of plasma metabolism markers in preparation of a reagent product for pulmonary nodule diagnosis, and relates to the technical field of disease diagnosis reagents. The metabolic marker is prepared from trigonelline, 4-methylcatechol, 2, 4-dinitrophenol, 3, 4-dihydroxyphenylacetic acid, N-(2-furfuryl) glycine, mevalonic acid and formononetin, and the metabolic marker is prepared from the following raw materials: the trigonelline, the 4-methylcatechol, the 2, 4-dinitrophenol, the 3, 4-dihydroxyphenylacetic acid, the N-( According to the application, ultra-high performance liquid chromatography-high resolution mass spectrometry (UPLC / MS) is adopted to carry out metabonomics analysis on plasma samples before and after an early pulmonary nodule operation, and a group of plasma metabolites (trigonelline, 4-methylcatechol, 2, 4-dinitrophenol, 3, 4-dihydroxyphenylacetic acid, N-(2-furfuryl) glycine, mevalonic acid and formononetin) are identified; and the group of metabolites is utilized to form a diagnosis model, so that benign and malignant pulmonary nodules can be accurately diagnosed, and early-stage differential diagnosis and risk assessment are facilitated.

The invention relates to a composite nano-system, a preparation method and application, the composite nano-system is a lipid-polymer hybrid nanoparticle with a core-shell structure, and the composite nano-system comprises: a hydrophobic core which is composed of a biodegradable polymer and cholesterol and is encapsulated with a hydrophobic drug formononetin; the middle layer is composed of cation / ionized lipid and auxiliary lipid and is used for loading negatively charged anti-KRAS siRNA through electrostatic interaction to form a stable compound, and the stable compound and the hydrophobic core jointly form nanoparticles; the shell layer is composed of pegylated lipid and a targeting ligand, and the targeting ligand is tLyp-1 peptide and is covalently linked to the tail end of the pegylated lipid through a maleimide-sulfydryl click chemical reaction. The system has excellent stability, biocompatibility and tumor targeting ability, can synergistically inhibit the growth of KRAS mutation pancreatic cancer, and relates to an application of the system in preparation of drugs for treating such cancers.

The invention belongs to the technical field of network pharmacology and molecular docking, and discloses a method for analyzing the treatment of renal fibrosis by formononetin based on the network pharmacology and molecular docking technology. Comprising the following steps: acquiring targets corresponding to active components, collecting renal fibrosis related targets, constructing a formononetin renal fibrosis target PPI network, performing enrichment analysis on core targets GO and KEGG, and performing molecular docking. Based on an integrated pharmacology platform and molecular docking, the mechanism of formononetin for treating renal fibrosis is explored, and the action mechanism of formononetin for treating renal fibrosis and related target genes are found and predicted.

The invention relates to application of formononetin in preparation of drugs, food or health care products for preventing or treating liver cancer related to non-alcoholic fatty liver disease or non-alcoholic fatty liver disease. According to the formononetin disclosed by the invention, the liver weight, the liver weight ratio, the tumor quantity and the maximum diameter of the tumor of a mouse with the non-alcoholic fatty liver-related liver cancer are remarkably reduced; in histology, the formononetin obviously improves fatty degeneration of liver tissues and liver lipid droplet density, and improves inflammation and fibrosis degree of liver cells; the formononetin obviously reduces the cholesterol serum content and the cholesterol content in the liver of a mouse with the non-alcoholic fatty liver related liver cancer, and reduces the liver injury indexes ALT and AST; the formononetin obviously reduces the expression level of mRNA (messenger ribonucleic acid) related to liver fibrosis of mice with liver cancer related to non-alcoholic fatty liver.

The invention discloses a formononetin derivative containing indole as well as a preparation method and application of the formononetin derivative, and belongs to the technical field of pesticide synthesis. According to the invention, an indole group with good biological activity is introduced into a formononetin structure, a series of formononetin derivatives containing indole are designed and synthesized, and the synthesized formononetin derivatives containing indole are subjected to plant pathogen inhibition activity tests. It is found that the derivative can effectively inhibit various plant pathogenic fungi, and especially shows the strongest inhibitory activity on Phomopsis kiwifruit.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

This invention relates to the field of biotechnology, specifically to the construction and application of a Benzodiacetic tobacco chassis for synthesizing isoflavones. This invention reconstructs the upstream pathway for isoflavone synthesis in Benzodiacetic tobacco, further identifies and screens key rate-limiting enzymes for isoflavone synthesis in Benzodiacetic tobacco, and utilizes 2A peptides to co-express multiple key genes, further introducing flavonoid synthesis transcription factors to construct a Benzodiacetic tobacco chassis for synthesizing isoflavones. This Benzodiacetic tobacco chassis can efficiently synthesize daidzein and genistein. Furthermore, based on the constructed high-yield Benzodiacetic tobacco platform for daidzein and genistein, various isoflavones can be further synthesized, such as daidzein, genistein, puerarin, gentiopicrin, chickpea extract A, and stigmosiderin, paving the way for the industrialization of plant biosynthesis of various bioactive isoflavones and thus possessing broad application prospects.

The invention discloses a traditional Chinese medicine composition and application, and relates to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition comprises, by weight, 1 part of sinomenine and 0.5-1.5 parts of formononetin, and the traditional Chinese medicine composition is used for treating chicken mycoplasma synoviae. As an innovative therapy for treating chicken mycoplasma synoviae, the traditional Chinese medicine composition provides an efficient and resistance-free treatment choice for farmers due to the characteristics of simple formula and easiness in obtaining. The traditional Chinese medicine composition is only composed of two traditional Chinese medicines, the cost is reduced, the preparation process is simplified, and large-scale application becomes possible. More importantly, the composition avoids negative effects caused by use of antibiotics and is especially suitable for the situation that antibiotics cannot be abused in laying hen breeding, a breeder can effectively control diseases and reduce economic losses under the situation that food safety regulations are not violated, the safety of poultry products is guaranteed, and the requirements of consumers for antibiotic-free products are met.

This invention belongs to the field of traditional Chinese medicine, specifically relating to a purified flavonoid from Sophora flavescens, its preparation method, and its application. Using Sophora flavescens as raw material, this invention extracts and separates purified flavonoid KSF50, and uses liquid chromatography-mass spectrometry (LC-MS / MS) to analyze and identify its components, determining its main functional groups and composition. The purified flavonoid from Sophora flavescens mainly contains the following six flavonoid components: daidzein, gentiopicrin, matrine O, trifolin stigmosiderin, matrine, and sophoridine. Furthermore, based on a high-sugar diet-induced *C. elegans* model and a high-sugar-induced 3T3-L1 preadipocyte model, this invention provides evidence that Sophora flavescens flavonoids can delay the aging of *C. elegans* by regulating lipid metabolism disorders, providing a theoretical basis for its application in medicine, cosmetics, and health functional foods.

The invention provides an application of a methoxy isoflavone compound in prevention and treatment of premature ovarian failure. A large number of studies find that the biochanin A and formononetin can effectively improve ovarian reserve function decline or estrus cycle disorder caused by premature senility, adjust the estrogen level, promote follicle development and maturity, increase the ovarian index, increase ovarian reserve and recover the ovarian function. Meanwhile, the biochanin A and the formononetin have the advantages of good stability, high biological activity and low toxicity, can be safely used for preparing medicines for preventing or / and treating ovarian reserve hypofunction and premature senility, and have good patent medicine prospects.

The present application relates to the chemical medicine field, specifically, a kind of formononetin derivative, preparation method and its application, the compound has significant proliferation inhibitory effect to EGFR high expression tumor cell, and activity is significantly better than formononetin;To EGFR low expression tumor cell and normal cell, toxicity is lower, has good target selectivity and biocompatibility;To A431 and HCC827 cell EGFR phosphorylation has good inhibitory effect, and it is dose-dependent;The compound mainly kills tumor cell by inducing apoptosis, with the gradual increase of compound concentration, early apoptotic cell and late apoptotic cell number also gradually increase, it is explained that compound mainly kills tumor cell by inducing apoptosis, provides potential candidate for developing new EGFR targeted antitumor drug, has important research value and application prospect.

The invention relates to the technical field of hedysarum polybotrys processing, in particular to a processing method for improving the quality of hedysarum polybotrys by adopting kneading sweating, which comprises the following steps: S1, digging and pretreatment; s2, performing airing treatment; s3, carrying out refined kneading treatment; s4, performing sweating treatment by stages; s5, drying and shaping treatment; through diameter classification and multi-step refined kneading, the problems of poor skin and flesh fitting and strip shape bending during processing can be avoided, the final finished product radix hedysari is oily and compact in appearance, the quality of the radix hedysari is improved, the content of formononetin in the finished product radix hedysari can be improved by means of a core technology of staged sweating, the content of effective components is stable, and the medicinal value is improved. By means of ozone disinfection before sweating, cushion layer high-temperature sterilization, mildew early warning treatment and accurate moisture detection, the problem of loss caused by mildew and excessive moisture during processing can be prevented, and the quality of the hedysarum polybotrys is further improved.

The application discloses application of berberine combined with formononetin in preparation of an antitumor drug, and particularly relates to treatment of nasopharyngeal carcinoma. After the two drugs are combined, an unexpected synergistic effect exists, and no toxic side effect is caused, so that the application has great application value in treatment of nasopharyngeal carcinoma.

The invention discloses an isoxazole-containing formononetin derivative as well as a preparation method and application thereof, and belongs to the technical field of pesticide synthesis. According to the invention, an isoxazole group with excellent activity is introduced into the structure of formononetin, a series of formononetin derivatives containing isoxazole are synthesized, and the activity of the synthesized formononetin derivatives containing isoxazole in inhibiting plant pathogenic fungi is tested. It is found that the isoxazole-containing formononetin derivative synthesized by the invention can effectively inhibit plant pathogenic fungi, especially phomopsis kiwifruit (Ps).

The application discloses flavonoid compounds with neuroprotective activity, and a preparation method and application thereof, and particularly relates to four specific ester derivatives of formononetin, namely, an allyl carbonate derivative (compound A), a 2-chlorobenzoic acid ester derivative (compound B), a cinnamic acid ester derivative (compound C), and a propionic acid ester derivative (compound D). The application significantly improves the defects of the parent compound, such as poor liposolubility, low blood-brain barrier permeability and low bioavailability, through specific ester group modification. Experiments show that the lipid-water partition coefficients and bioavailability of the four types of derivatives are significantly improved compared with the parent compound. In addition, the four types of derivatives show better neuroprotective activity than the parent compound and a positive control drug in Alzheimer's disease and Parkinson's disease models, and show a synergistic effect between the parent compound and the modification group. The application further provides a preparation method of the above compounds and application of the above compounds in preparation of drugs for treating neurodegenerative diseases.

The invention discloses a novel application of formononetin in preparation of a medicine for maintaining the dryness of alveolar II epithelial cells, formononetin is definitely used for preparing the medicine for maintaining the dryness of alveolar II epithelial cells, in-vivo and in-vitro experiments verify the repairing effect of formononetin on ATII dryness injury, the technical blank of intervention of natural active ingredients in ATII dryness is filled, and the application of formononetin in preparation of the medicine for maintaining the dryness of alveolar II epithelial cells is developed. The formononetin is used as a raw material, a new way which is efficient, low in cost and easy to obtain is provided for ATII dry maintenance, the concentration of a medicine prepared by using the formononetin is screened, an important theoretical basis is provided for further medication and medicine preparation, meanwhile, the pharmacological application range of the formononetin is expanded, and the application prospect is wide. A brand new treatment strategy is provided for lung diseases such as acute lung injury, pulmonary fibrosis and the like which are characterized by ATII dry failure.